Abstract
Background: The Renin-Angiotensin System (RAS) is a key regulator of cardiovascular and renal homeostasis, but also plays important roles in mediating physiological functions in the central nervous system (CNS). The effects of the RAS were classically described as mediated by angiotensin (Ang) II via angiotensin type 1 (AT1) receptors. However, another arm of the RAS formed by the angiotensin converting enzyme 2 (ACE2), Ang-(1-7) and the Mas receptor has been a matter of investigation due to its important physiological roles, usually counterbalancing the classical effects exerted by Ang II.
Objective: We aim to provide an overview of effects elicited by the RAS, especially Ang-(1-7), in the brain. We also aim to discuss the therapeutic potential for neuropsychiatric disorders for the modulation of RAS.
Method: We carried out an extensive literature search in PubMed central.
Results: Within the brain, Ang-(1-7) contributes to the regulation of blood pressure by acting at regions that control cardiovascular functions. In contrast with Ang II, Ang-(1-7) improves baroreflex sensitivity and plays an inhibitory role in hypothalamic noradrenergic neurotransmission. Ang-(1-7) not only exerts effects related to blood pressure regulation, but also acts as a neuroprotective component of the RAS, for instance, by reducing cerebral infarct size, inflammation, oxidative stress and neuronal apoptosis.
Conclusion: Pre-clinical evidence supports a relevant role for ACE2/Ang-(1-7)/Mas receptor axis in several neuropsychiatric conditions, including stress-related and mood disorders, cerebrovascular ischemic and hemorrhagic lesions and neurodegenerative diseases. However, very few data are available regarding the ACE2/Ang-(1-7)/Mas receptor axis in human CNS.
Keywords: Renin-angiotensin system, brain, angiotensin-converting enzyme, angiotensin-(1-7), mas receptor, neuropsychiatry.
Current Medicinal Chemistry
Title:RAS in the Central Nervous System: Potential Role in Neuropsychiatric Disorders
Volume: 25 Issue: 28
Author(s): Natalia Pessoa Rocha, Ana Cristina Simoes e Silva, Thiago Ruiz Rodrigues Prestes, Victor Feracin, Caroline Amaral Machado, Rodrigo Novaes Ferreira, Antonio Lucio Teixeira and Aline Silva de Miranda*
Affiliation:
- Laboratorio Interdisciplinar de Investigacao Medica (LIIM), Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte,Brazil
Keywords: Renin-angiotensin system, brain, angiotensin-converting enzyme, angiotensin-(1-7), mas receptor, neuropsychiatry.
Abstract: Background: The Renin-Angiotensin System (RAS) is a key regulator of cardiovascular and renal homeostasis, but also plays important roles in mediating physiological functions in the central nervous system (CNS). The effects of the RAS were classically described as mediated by angiotensin (Ang) II via angiotensin type 1 (AT1) receptors. However, another arm of the RAS formed by the angiotensin converting enzyme 2 (ACE2), Ang-(1-7) and the Mas receptor has been a matter of investigation due to its important physiological roles, usually counterbalancing the classical effects exerted by Ang II.
Objective: We aim to provide an overview of effects elicited by the RAS, especially Ang-(1-7), in the brain. We also aim to discuss the therapeutic potential for neuropsychiatric disorders for the modulation of RAS.
Method: We carried out an extensive literature search in PubMed central.
Results: Within the brain, Ang-(1-7) contributes to the regulation of blood pressure by acting at regions that control cardiovascular functions. In contrast with Ang II, Ang-(1-7) improves baroreflex sensitivity and plays an inhibitory role in hypothalamic noradrenergic neurotransmission. Ang-(1-7) not only exerts effects related to blood pressure regulation, but also acts as a neuroprotective component of the RAS, for instance, by reducing cerebral infarct size, inflammation, oxidative stress and neuronal apoptosis.
Conclusion: Pre-clinical evidence supports a relevant role for ACE2/Ang-(1-7)/Mas receptor axis in several neuropsychiatric conditions, including stress-related and mood disorders, cerebrovascular ischemic and hemorrhagic lesions and neurodegenerative diseases. However, very few data are available regarding the ACE2/Ang-(1-7)/Mas receptor axis in human CNS.
Export Options
About this article
Cite this article as:
Rocha Pessoa Natalia, Simoes e Silva Cristina Ana, Prestes Ruiz Rodrigues Thiago, Feracin Victor, Machado Amaral Caroline, Ferreira Novaes Rodrigo , Teixeira Lucio Antonio and de Miranda Silva Aline*, RAS in the Central Nervous System: Potential Role in Neuropsychiatric Disorders, Current Medicinal Chemistry 2018; 25 (28) . https://dx.doi.org/10.2174/0929867325666180226102358
DOI https://dx.doi.org/10.2174/0929867325666180226102358 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group
Recent Patents on Cardiovascular Drug Discovery Polydeoxyribonucleotide (PDRN): A Safe Approach to Induce Therapeutic Angiogenesis in Peripheral Artery Occlusive Disease and in Diabetic Foot Ulcers
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Patents on Drugs Addressing Neurodegenerative Diseases
Recent Patents on Biomarkers Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches
Current Pharmaceutical Biotechnology Treatments for Hypertension in Type 2 Diabetes-Non-pharmacological and Pharmacological Measurements<sup>#</sup>
Current Hypertension Reviews Cerebrovascular Profile Assessment in Parkinson's Disease Patients
CNS & Neurological Disorders - Drug Targets Folate and Homocysteine Metabolism: Therapeutic Targets in Cardiovascular and Neurodegenerative Disorders
Current Medicinal Chemistry Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry Defective Insulin Signalling, Mediated by Inflammation, Connects Obesity to Alzheimer Disease; Relevant Pharmacological Therapies and Preventive Dietary Interventions
Current Alzheimer Research Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Current Pharmaceutical Design Phytotherapeutics against Alzheimer’s Disease: Mechanism, Molecular Targets and Challenges for Drug Development
CNS & Neurological Disorders - Drug Targets Prospects for Early Detection of Alzheimers Disease from Serial MR Images in Transgenic Mouse Models
Current Alzheimer Research Neuroproteomics: Are We Biased in Our Representation of Molecular Targets Associated with Specific Domains? Implications in Biomarker Discovery
Current Proteomics Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery A Novel Finding: Macrophages Involved in Inflammation Participate in Acute Aortic Dissection Complicated with Acute Lung Injury
Current Molecular Medicine Targets of Antidementive Therapy: Drugs with a Specific Pharmacological Mechanism of Action
Current Pharmaceutical Design Synthesis, Physico-Chemical Properties and DFT Calculations of New 2-(4- Arylpiperazine-1-yl)-1-(3-ethylbenzofuran-2-yl)ethanols As Potential Antihypertensive Agents
Current Organic Chemistry Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Inflammation as Therapeutic Objective in Stroke
Current Pharmaceutical Design